Pay in 4 interest-free payments of $34.50 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
The facilitation of GluN2C/GluN2D-containing receptors may serve as an important therapeutic strategy for treating positive and cognitive symptoms in schizophrenia
CAS Number: 77086-22-7
especially the alpha-1 subunit
which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution
14814/phy2
Taranabant - CAS# 701977-09-5 Catalog No.:M10861-2 The facilitation of GluN2C/GluN2D-containing receptorsTaranabant, aslo known as MK 0364, a cannabinoid receptor type 1 inverse agonist being investigated as a potential treatment for obesity due to its anorectic effects. Taranabant reduces abdominal pain and increases intestinal transit in mice. It was discovered by Merck & Co. In October 2008, Merck has stopped its phase III clinical trials with the drugs due to high level of central side effects, mainly depression and anxiety. Product information CAS
US$ 2975.00
US$ 37.71
US$ 178.23
US$ 89.78
US$ 14.39